title: Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
abstract: Peripheral T-cell lymphoma is a heterogenous non-Hodgkin Lymphoma with historically poor outcomes. Currently, response rates remain poor with traditional chemotherapy and many of those responding to initial therapy will relapse. Belinostat (Beleodaq, Spectrum Pharmaceuticals) is a histone deacetylase inhibitor (HDACi) approved for use in relapsed or refractory peripheral T-cell lymphoma (PTCL). Belinostat is metabolized hepatically through cytochrome P-450 enzymes 3A4, 2C9, and 2A6; however, no empiric dosage adjustments of belinostat are recommended during concurrent use of inhibitors or inducers of these enzymes. Belinostat's efficacy has been evaluated in a clinical trial showing an overall response rate (ORR) of 25.8% and a median duration of response of 8.4 months. Belinostat is generally well tolerated, with the most common adverse reactions (>25%) being nausea, vomiting, fatigue, pyrexia, and anemia in patients with relapsed or refractory PTCL. Belinostat is a safe and effective treatment option for relapsed and refractory peripheral T-cell lymphoma, with many future applications currently being investigated.
authors.affiliation: 1 Department of Pharmacy, NewYork-Presbyterian Hospital, University Hospital of Columbia and Cornell, New York, USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Campbell
authors.affiliation: 1 Department of Pharmacy, NewYork-Presbyterian Hospital, University Hospital of Columbia and Cornell, New York, USA.|2 Department of Clinical Health Professions, College of Pharmacy, St. John's University, New York, USA.
authors.forename: Christan M
authors.initials: CM
authors.lastname: Thomas
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001772:Blood Cell Count; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016411:Lymphoma, T-Cell, Peripheral / Q000097:blood / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D056572:Histone Deacetylase Inhibitors; D006877:Hydroxamic Acids; D013449:Sulfonamides; C487081:belinostat
keywords: Hematology; lymphoma; oncology